Karen Kelly

Title(s)Professor, Hematology and Oncology
SchoolSchool of Medicine
AddressCancer Ctr So, #3016
CA 95817
Phone916-734-3735
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. Clin Cancer Res. 2024 Jan 26. Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst R, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. PMID: 38277235.
      View in: PubMed   Mentions:    Fields:    
    2. Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042). Clin Cancer Res. 2023 09 15; 29(18):3641-3649. Gadgeel SM, Miao J, Riess JW, Moon J, Mack PC, Gerstner GJ, Burns TF, Taj A, Akerley WL, Dragnev KH, Laudi N, Redman MW, Gray JE, Gandara DR, Kelly K. PMID: 37233987; PMCID: PMC10526968.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    3. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol. 2023 10; 18(10):1290-1302. Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne MT, Connolly C, Wynes M, Bota-Rabassedas N, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou TY, Kerr K, Nicholson A, Poleri C, Schalper KA, Tsao MS, Carbone DP, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA, Kris MG, Belani CP, Kelly K, Wistuba I, IASLC Pathology Committee. PMID: 37702631.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial. Nat Commun. 2023 09 02; 14(1):5332. Monjazeb AM, Daly ME, Luxardi G, Maverakis E, Merleev AA, Marusina AI, Borowsky A, Mirhadi A, Shiao SL, Beckett L, Chen S, Eastham D, Li T, Vick LV, McGee HM, Lara F, Garcia L, Morris LA, Canter RJ, Riess JW, Schalper KA, Murphy WJ, Kelly K. PMID: 37658083; PMCID: PMC10474145.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    5. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). JCO Precis Oncol. 2023 09; 7:e2300218. Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, Blanke CD, LeBlanc ML, Kelly K, Gray JE, Redman MW. PMID: 37677122; PMCID: PMC10581630.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Emotional Distress, Anxiety, and General Health Status in Patients With Newly Identified Small Pulmonary Nodules: Results From the Watch the Spot Trial. Chest. 2023 Dec; 164(6):1560-1571. Gould MK, Creekmur B, Qi L, Golden SE, Kaplan CP, Walter E, Mularski RA, Vaszar LT, Fennig K, Steiner J, de Bie E, Musigdilok VV, Altman DA, Dyer DS, Kelly K, Miglioretti DL, Wiener RS, Slatore CG, Smith-Bindman R. PMID: 37356710.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdac183. Carneiro BA, Papadopoulos KP, Strickler JH, Lassman AB, Waqar SN, Chae YK, Patel JD, Shacham-Shmueli E, Kelly K, Khasraw M, Bestvina CM, Merrell R, Huang K, Atluri H, Ansell P, Li R, Jin J, Anderson MG, Reilly EB, Morrison-Thiele G, Patel K, Robinson RR, Aristide MRN, Gan HK. PMID: 36814898; PMCID: PMC9940695.
      View in: PubMed   Mentions: 1  
    8. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clin Res Rep. 2022 Dec; 3(12):100427. Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. PMID: 36426286; PMCID: PMC9679033.
      View in: PubMed   Mentions: 5  
    9. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. PMID: 36288547; PMCID: PMC9928626.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    10. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). Clin Cancer Res. 2022 09 01; 28(17):3752-3760. Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. PMID: 35713632; PMCID: PMC9444942.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    11. A Case of Osimertinib-Induced Eosinophilic Pneumonia. Clin Lung Cancer. 2022 Nov; 23(7):639-642. Patel KG, Corbett RL, Karanjawala ZE, Kelly KA, Stollenwerk N, Riess JW. PMID: 36104273.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol. 2022 07 20; 40(21):2295-2306. Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. PMID: 35658002; PMCID: PMC9287284.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    13. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA Oncol. 2022 05 01; 8(5):717-728. Kehl KL, Zahrieh D, Yang P, Hillman SL, Tan AD, Sands JM, Oxnard GR, Gillaspie EA, Wigle D, Malik S, Stinchcombe TE, Ramalingam SS, Kelly K, Govindan R, Mandrekar SJ, Osarogiagbon RU, Kozono D. PMID: 35297944; PMCID: PMC8931674.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    14. Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor. Future Oncol. 2022 Apr; 18(11):1333-1342. Hrinczenko B, Iannotti N, Goel S, Spigel D, Safran H, Taylor MH, Bennouna J, Wong DJ, Kelly K, Verschraegen C, Bajars M, Manitz J, Ruisi M, Gulley JL. PMID: 35144482; PMCID: PMC9066292.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    15. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. J Exp Clin Cancer Res. 2022 Feb 07; 41(1):51. Voon PJ, Chen EX, Chen HX, Lockhart AC, Sahebjam S, Kelly K, Vaishampayan UN, Subbiah V, Razak AR, Renouf DJ, Hotte SJ, Singh A, Bedard PL, Hansen AR, Ivy SP, Wang L, Stayner LA, Siu LL, Spreafico A. PMID: 35130943; PMCID: PMC8819907.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    16. Risk factors for musculoskeletal injuries in the military: a qualitative systematic review of the literature from the past two decades and a new prioritizing injury model. Mil Med Res. 2021 12 10; 8(1):66. Sammito S, Hadzic V, Karakolis T, Kelly KR, Proctor SP, Stepens A, White G, Zimmermann WO. PMID: 34886915; PMCID: PMC8662851.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    17. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clin Res Rep. 2022 Jan; 3(1):100262. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E, Hong DS, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K. PMID: 35005654; PMCID: PMC8717236.
      View in: PubMed   Mentions: 3  
    18. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 12; 19(12):1441-1464. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. PMID: 34902832; PMCID: PMC10203822.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    19. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clin Lung Cancer. 2022 01; 23(1):60-71. Hirsch FR, Redman MW, Moon J, Agustoni F, Herbst RS, Semrad TJ, Varella-Garcia M, Rivard CJ, Kelly K, Gandara DR, Mack PC. PMID: 34753703; PMCID: PMC8766941.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    20. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Sep 01; 7(9):1368-1377. Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. PMID: 34264316; PMCID: PMC8283667.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsCTClinical Trials
    21. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792. Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. PMID: 34426443.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    22. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). J Immunother Cancer. 2021 08; 9(8). Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR. PMID: 34429332; PMCID: PMC8386207.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    23. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. Target Oncol. 2021 07; 16(4):435-446. Tan B, Khattak A, Felip E, Kelly K, Rich P, Wang D, Helwig C, Dussault I, Ojalvo LS, Isambert N. PMID: 34009501; PMCID: PMC8266790.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    24. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clin Lung Cancer. 2021 11; 22(6):541-548. Riess JW, Reckamp KL, Frankel P, Longmate J, Kelly KA, Gandara DR, Weipert CM, Raymond VM, Keer HN, Mack PC, Newman EM, Lara PN. PMID: 34140248; PMCID: PMC9239707.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    25. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2021 08; 88(2):335-341. Semrad TJ, Kim EJ, Gong IY, Li T, Christensen S, Arora M, Riess JW, Gandara DR, Kelly K. PMID: 33993383; PMCID: PMC8259450.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    26. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy. 2021 06; 13(9):727-734. Sands JM, Mandrekar SJ, Kozono D, Oxnard GR, Hillman SL, Wigle DA, Govindan R, Carlisle J, Gray J, Salama JK, Raez L, Ganti A, Foster N, Malik S, Bradley J, Kelly K, Ramalingam SS, Stinchcombe TE. PMID: 33878954; PMCID: PMC8293026.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    27. Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncol Pract. 2021 11; 17(11):e1821-e1829. Roth JA, Trivedi MS, Gray SW, Patrick DL, Delaney DM, Watabayashi K, Litwin P, Shah P, Crew KD, Yee M, Redman MW, Unger JM, Papadimitrakopoulou V, Johnson J, Kelly K, Gandara D, Herbst RS, Hershman DL, Ramsey SD. PMID: 33797955.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. IMpower 132: Loses Power at the Finish Line. J Thorac Oncol. 2021 04; 16(4):512-514. Patel SP, Kelly K. PMID: 33781439.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Clin Lung Cancer. 2021 07; 22(4):313-323.e1. Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR. PMID: 33745865; PMCID: PMC8562492.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    30. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021 02; 9(2). Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. PMID: 33608377; PMCID: PMC7898862.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    31. Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 1. McCoach CE, Yu A, Gandara DR, Riess JW, Vang DP, Li T, Lara PN, Gubens M, Lara F, Mack PC, Beckett LA, Kelly K. PMID: 34036220; PMCID: PMC8140807.
      View in: PubMed   Mentions: 11     Fields:    
    32. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021 05; 22(3):187-194.e1. Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. PMID: 33583720; PMCID: PMC8637652.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    33. Guidelines for the Evaluation of Pulmonary Nodules Detected Incidentally or by Screening: A Survey of Radiologist Awareness, Agreement, and Adherence From the Watch the Spot Trial. J Am Coll Radiol. 2021 Apr; 18(4):545-553. Gould MK, Altman DE, Creekmur B, Qi L, de Bie E, Golden S, Kaplan CP, Kelly K, Miglioretti DL, Mularski RA, Musigdilok VV, Smith-Bindman R, Steltz JP, Wiener RS, Aberle DR, Dyer DS, Vachani A. PMID: 33212069.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Clin Lung Cancer. 2021 05; 22(3):178-186. Borghaei H, Redman MW, Kelly K, Waqar SN, Robert F, Kiefer GJ, Stella PJ, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou VA. PMID: 33358401; PMCID: PMC8686189.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    35. Efficacy and immune-related adverse event associations in avelumab-treated patients. J Immunother Cancer. 2020 11; 8(2). Kelly K, Manitz J, Patel MR, D'Angelo SP, Apolo AB, Rajan A, Kasturi V, Speit I, Bajars M, Warth J, Gulley JL. PMID: 33219092; PMCID: PMC7682456.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    36. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 12; 21(12):1589-1601. Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. PMID: 33125909; PMCID: PMC8109255.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    37. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clin Lung Cancer. 2021 05; 22(3):170-177. Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. PMID: 33221175; PMCID: PMC8044254.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    38. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. J Clin Oncol. 2020 12 01; 38(34):4076-4085. Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR. PMID: 33021871; PMCID: PMC7768342.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    39. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. J Immunother Cancer. 2020 09; 8(2). Verschraegen CF, Jerusalem G, McClay EF, Iannotti N, Redfern CH, Bennouna J, Chen FL, Kelly K, Mehnert J, Morris JC, Taylor M, Spigel D, Wang D, Grote HJ, Zhou D, Munshi N, Bajars M, Gulley JL. PMID: 32907924; PMCID: PMC7481079.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    40. Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. Clin Cancer Res. 2020 10 15; 26(20):5329-5337. Connolly RM, Laille E, Vaishampayan U, Chung V, Kelly K, Dowlati A, Alese OB, Harvey RD, Haluska P, Siu LL, Kummar S, Piekarz R, Ivy SP, Anders NM, Downs M, O'Connor A, Scardina A, Saunders J, Rosner GL, Carducci MA, Rudek MA, ETCTN-9008 Study Team. PMID: 32816943; PMCID: PMC7572570.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    41. Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study. JCO Precis Oncol. 2019 Dec; 3:1-10. Peguero J, Sohal DPS, O'Neil BH, Safran H, Kelly K, Grilley-Olson JE, Subbiah V, Nadauld L, Purkayastha D, Stealey E, Ricart AD, Kang BP, Eder JP. PMID: 35100715.
      View in: PubMed   Mentions: 5     Fields:    
    42. Methods for the Watch the Spot Trial. A Pragmatic Trial of More- versus Less-Intensive Strategies for Active Surveillance of Small Pulmonary Nodules. Ann Am Thorac Soc. 2019 12; 16(12):1567-1576. Gould MK, Smith-Bindman R, Kelly K, Altman DE, Barjaktarevic I, Creekmur B, de Bie E, Dyer DS, Mortani Barbosa EJ, Mularski RA, Qi L, Vaszar LT, Yu S, Miglioretti DL. PMID: 31314549.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    43. Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. Front Oncol. 2019; 9:1256. Goldman JW, Waterhouse DM, George B, O'Dwyer PJ, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, Kelly K. PMID: 31850192; PMCID: PMC6901975.
      View in: PubMed   Mentions: 4  
    44. CT Volumetry and Basic Texture Analysis as Surrogate Markers in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):225-231. Owen B, Gandara D, Kelly K, Moore E, Shelton D, Knollmann F. PMID: 31699509.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    45. Hormonal balance and nutritional intake in elite tactical athletes. Steroids. 2019 12; 152:108504. Jensen AE, Arrington LJ, Turcotte LP, Kelly KR. PMID: 31586604.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    46. Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non-small-cell Lung Cancer. Clin Lung Cancer. 2020 01; 21(1):e15-e20. Al-Obeidi E, Li T, Kelly K. PMID: 31649001.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    47. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019 10 01; 37(28):2537-2547. Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. PMID: 31386610; PMCID: PMC7001793.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    48. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1853-1859. Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. PMID: 31302234; PMCID: PMC6764876.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    49. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1847-1852. Aggarwal C, Redman MW, Lara PN, Borghaei H, Hoffman P, Bradley JD, Newman AJ, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. PMID: 31195180; PMCID: PMC6901020.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    50. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019 10; 14(10):1839-1846. Langer CJ, Redman MW, Wade JL, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA. PMID: 31158500; PMCID: PMC7017958.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    51. Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. Oncologist. 2019 09; 24(9):1270-1284. Abdel Karim N, Kelly K. PMID: 30914465; PMCID: PMC6738296.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    52. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019 03 01; 5(3):393-401. Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. PMID: 30676622; PMCID: PMC6439837.
      View in: PubMed   Mentions: 193     Fields:    Translation:HumansCTClinical Trials
    53. Clinical prognostic model for older patients with advanced non-small cell lung cancer. J Geriatr Oncol. 2019 07; 10(4):555-559. Ganti AK, Wang X, Stinchcombe TE, Wang Y, Bradley J, Cohen HJ, Kelly K, Paulus R, Ramalingam SS, Vokes EE, Pang H. PMID: 30797707; PMCID: PMC7136030.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    54. Response to H. Nabi et al. J Natl Cancer Inst. 2018 12 01; 110(12):1424-1425. Cheng TD, Darke AK, Redman MW, Kelly K, Santella RM, Albain KS, Ambrosone CB. PMID: 29688488; PMCID: PMC6658869.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS One. 2018; 13(11):e0208097. Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA. PMID: 30481207; PMCID: PMC6258560.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    56. Survival benefits associated with surgery for advanced non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019 04; 157(4):1620-1628. David EA, Andersen SW, Beckett LA, Melnikow J, Clark JM, Brown LM, Cooke DT, Kelly K, Canter RJ. PMID: 30551965; PMCID: PMC6448577.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    57. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019 01; 25(1):141-151. Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. PMID: 30420753; PMCID: PMC6324991.
      View in: PubMed   Mentions: 340     Fields:    Translation:HumansAnimalsCells
    58. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 02; 14(2):298-303. Schild SE, Fan W, Stinchcombe TE, Vokes EE, Ramalingam SS, Bradley JD, Kelly K, Pang HH, Wang X. PMID: 30292852; PMCID: PMC6348032.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    59. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 11 20; 36(33):3298-3306. Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. PMID: 30285518.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    60. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer. 2018 11; 19(6):531-543. Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR. PMID: 30197261; PMCID: PMC6204301.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 10; 82(4):723-732. Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM. PMID: 30128950; PMCID: PMC6342617.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    62. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. Clin Cancer Res. 2018 11 15; 24(22):5543-5551. Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW. PMID: 30082474.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    63. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. Clin Lung Cancer. 2018 11; 19(6):e853-e859. Barbie DA, Spira A, Kelly K, Humeniuk R, Kawashima J, Kong S, Koczywas M. PMID: 30087028; PMCID: PMC6420784.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    64. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst. 2018 07 01; 110(7):734-742. Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB. PMID: 29346580; PMCID: PMC6037104.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    65. Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1259-1270. McGee HM, Daly ME, Azghadi S, Stewart SL, Oesterich L, Schlom J, Donahue R, Schoenfeld JD, Chen Q, Rao S, Fragoso RC, Valicenti RK, Canter RJ, Maverakis EM, Murphy WJ, Kelly K, Monjazeb AM. PMID: 29891204; PMCID: PMC6364565.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    66. Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. J Thorac Oncol. 2018 08; 13(8):1171-1182. Schild SE, Pang HH, Fan W, Stinchcombe TE, Vokes EE, Ramalingam SS, Bradley JD, Kelly K, Wang X. PMID: 29689435.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    67. Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. Clin Lung Cancer. 2018 09; 19(5):377-386. Shukla ND, Salahudeen AA, Taylor GA, Ramalingam SS, Vokes EE, Goss GD, Decker RH, Kelly K, Scagliotti GV, Mok TS, Wakelee HA. PMID: 29653819.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    68. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018 05 01; 124(9):2010-2017. Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL. PMID: 29469949; PMCID: PMC5947549.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    69. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 01; 19(1):101-114. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. PMID: 29169877; PMCID: PMC5847342.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    70. The Ever-Increasing Number of Trial Eligibility Criteria: Time to Bend the Curve. J Thorac Oncol. 2017 10; 12(10):1459-1460. Bradley J, Kelly K, Stinchcombe TE. PMID: 28939144.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    71. Infusion-related reactions with administration of avelumab: mild and manageable side effects. Transl Cancer Res. 2017 Oct; 6(Suppl 7):S1296-S1298. Gulley JL, Kelly K. PMID: 32999863; PMCID: PMC7523879.
      View in: PubMed   Mentions: 2  
    72. A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients. Ann Thorac Surg. 2017 Nov; 104(5):1665-1672. David EA, Andersen SW, Beckett LA, Melnikow J, Kelly K, Cooke DT, Brown LM, Canter RJ. PMID: 28964421; PMCID: PMC7491367.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    73. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. Lung Cancer. 2017 10; 112:165-168. Lara JD, Brunson A, Riess JW, Kelly K, Lara PN, Gandara DR. PMID: 29191590.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    74. The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 11; 12(11):1636-1645. David EA, Clark JM, Cooke DT, Melnikow J, Kelly K, Canter RJ. PMID: 28843357; PMCID: PMC5690551.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    75. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer. 2018 01; 19(1):84-92. West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. PMID: 28801183; PMCID: PMC5748264.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    76. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol. 2017 08; 12(8):1299-1308. Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K. PMID: 28599887; PMCID: PMC5690479.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    77. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892. Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X. PMID: 28493811; PMCID: PMC5578390.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    78. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017 06; 18(6):803-811. Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, Beron P, Wong D, Rosove MH, Rao S, Melanson H, Kim E, Palmer D, Qi L, Kelly K, Steinberg ML, Kupelian PA, Daly ME. PMID: 28434660; PMCID: PMC6488353.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCellsCTClinical Trials
    79. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol. 2017 Jul 01; 35(19):2117-2124. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. PMID: 28375787; PMCID: PMC5493051.
      View in: PubMed   Mentions: 269     Fields:    Translation:HumansCTClinical Trials
    80. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017 05; 18(5):599-610. Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJL, Leach J, Edenfield WJ, Wang D, Grote HJ, Heydebreck AV, Chin K, Cuillerot JM, Kelly K. PMID: 28373005; PMCID: PMC5522719.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansCTClinical Trials
    81. Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices. Brief Bioinform. 2017 03 01; 18(2):312-320. Taylor SL, Ruhaak LR, Kelly K, Weiss RH, Kim K. PMID: 26896791; PMCID: PMC5862252.
      View in: PubMed   Mentions: 19     Fields:    
    82. Treatment of Locally Advanced Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2017 02; 31(1):45-57. Tam K, Daly M, Kelly K. PMID: 27912833.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    83. Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis. J Thorac Oncol. 2017 03; 12(3):437-445. David EA, Daly ME, Li CS, Chiu CL, Cooke DT, Brown LM, Melnikow J, Kelly K, Canter RJ. PMID: 28109804; PMCID: PMC5510589.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    84. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN. PMID: 28082049.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    85. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 May; 18(3):281-285. Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara DR, Kelly K, Mack PC. PMID: 28038979; PMCID: PMC5837026.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    86. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566. Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G. PMID: 27876675.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    87. Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens. Bioinformatics. 2017 01 01; 33(1):17-25. Taylor SL, Ruhaak LR, Weiss RH, Kelly K, Kim K. PMID: 27592710; PMCID: PMC6075023.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    88. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 07; 11(7):946-63. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. PMID: 27229180.
      View in: PubMed   Mentions: 84     Fields:    Translation:Humans
    89. Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. Cancer Biomark. 2016 Mar 11; 16(4):609-17. Fahrmann JF, Grapov D, DeFelice BC, Taylor S, Kim K, Kelly K, Wikoff WR, Pass H, Rom WN, Fiehn O, Miyamoto S. PMID: 27002763.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    90. Exercise training with blood flow restriction has little effect on muscular strength and does not change IGF-1 in fit military warfighters. Growth Horm IGF Res. 2016 Apr; 27:33-40. Jensen AE, Palombo LJ, Niederberger B, Turcotte LP, Kelly KR. PMID: 26922387.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    91. Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer. Front Oncol. 2015; 5:301. Huang CH, Williamson SK, Neupane P, Taylor SA, Allen A, Smart NJ, Uypeckcuat AM, Spencer S, Wick J, Smith H, Van Veldhuizen PJ, Kelly K. PMID: 26793618; PMCID: PMC4710681.
      View in: PubMed   Mentions: 3  
    92. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1685-93. Daly ME, Monjazeb AM, Kelly K. PMID: 26484629.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    93. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-8.e1-2. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. PMID: 26498504; PMCID: PMC4789142.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    94. Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue. J Proteome Res. 2015 Nov 06; 14(11):4538-49. Ruhaak LR, Taylor SL, Stroble C, Nguyen UT, Parker EA, Song T, Lebrilla CB, Rom WN, Pass H, Kim K, Kelly K, Miyamoto S. PMID: 26322380; PMCID: PMC4644186.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    95. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2015 Dec 01; 33(34):4007-14. Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. PMID: 26324372.
      View in: PubMed   Mentions: 175     Fields:    Translation:HumansCTClinical Trials
    96. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer. 2015 Dec 01; 121(23):4165-72. Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY. PMID: 26308485; PMCID: PMC5941922.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    97. Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1716-23. Fahrmann JF, Kim K, DeFelice BC, Taylor SL, Gandara DR, Yoneda KY, Cooke DT, Fiehn O, Kelly K, Miyamoto S. PMID: 26282632; PMCID: PMC4633344.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    98. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 2016 Feb; 5(2):e1075114. Mall C, Sckisel GD, Proia DA, Mirsoian A, Grossenbacher SK, Pai CS, Chen M, Monjazeb AM, Kelly K, Blazar BR, Murphy WJ. PMID: 27057446; PMCID: PMC4801432.
      View in: PubMed   Mentions: 28     Fields:    
    99. Accelerated Hepatitis A and B Immunization in a Substance Abuse Treatment Program. Fed Pract. 2015 Aug; 32(8):38-43. Winn JL, Francis EM, Shealy SE, Levarge M, Paton S, Planner A, Kelly K, Gonzales-Nolas C. PMID: 30766082; PMCID: PMC6363320.
      View in: PubMed   Mentions:
    100. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. PMID: 26106072; PMCID: PMC4592395.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    101. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN. PMID: 25739672; PMCID: PMC4452427.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    102. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prev Res (Phila). 2015 May; 8(5):410-8. Wikoff WR, Grapov D, Fahrmann JF, DeFelice B, Rom WN, Pass HI, Kim K, Nguyen U, Taylor SL, Gandara DR, Kelly K, Fiehn O, Miyamoto S. PMID: 25657018; PMCID: PMC4618700.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    103. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7. Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. PMID: 25703100; PMCID: PMC4497941.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    104. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR. PMID: 25490004; PMCID: PMC4320001.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    105. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014 Aug 10; 32(23):2463-70. Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR. PMID: 25002722; PMCID: PMC4121504.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    106. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. Lung Cancer. 2014 Aug; 85(2):264-9. Lara MS, Brunson A, Wun T, Tomlinson B, Qi L, Cress R, Gandara DR, Kelly K. PMID: 24878033.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    107. Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer. 2014 Apr 01; 120 Suppl 7:1091-6. Chen MS, Lara PN, Dang JH, Paterniti DA, Kelly K. PMID: 24643646; PMCID: PMC3980490.
      View in: PubMed   Mentions: 191     Fields:    Translation:Humans
    108. 50 Years of progress in the systemic therapy of non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2014; 177-89. Wakelee H, Kelly K, Edelman MJ. PMID: 24857075; PMCID: PMC5600272.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimals
    109. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013 Dec; 8(12):1519-28. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. PMID: 24189513; PMCID: PMC4072123.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    110. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. PMID: 24176733; PMCID: PMC4586161.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    111. Treatment paradigms in advanced non-small-cell lung cancer. Clin Adv Hematol Oncol. 2013 Oct; 11(10):629-39. McCoach CE, Kelly K. PMID: 24518373.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    112. A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Front Oncol. 2013; 3:219. Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara DR. PMID: 24010120; PMCID: PMC3755267.
      View in: PubMed   Mentions: 4  
    113. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. PMID: 23910067; PMCID: PMC4122504.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    114. Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem. 2013 May; 405(14):4953-8. Ruhaak LR, Taylor SL, Miyamoto S, Kelly K, Leiserowitz GS, Gandara D, Lebrilla CB, Kim K. PMID: 23525540; PMCID: PMC3640767.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    115. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. PMID: 22677432; PMCID: PMC4049356.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    116. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. J Thorac Oncol. 2012 Jun; 7(6):1041-8. Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, Pereira JR, Juhász E, Iannotti NO, Weems G, Koutsoukos T, Patel JD. PMID: 22534814.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    117. N-Glycan profiling of dried blood spots. Anal Chem. 2012 Jan 03; 84(1):396-402. Ruhaak LR, Miyamoto S, Kelly K, Lebrilla CB. PMID: 22128873; PMCID: PMC3259271.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    118. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila). 2011 Jun; 4(6):793-802. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA, Geraci MW, Miller YE. PMID: 21636546; PMCID: PMC3251330.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    119. Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. J Thorac Oncol. 2011 Feb; 6(2):372-7. Huang CH, Williamson SK, Van Veldhuizen PJ, Hsueh CT, Allen A, Tawfik O, Wick J, Smith H, Uypeckcuat AM, Mayo M, Kelly K. PMID: 21178640.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    120. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 2011 Jan; 6(1):115-20. Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozniak AJ, Crowley J, Gandara D. PMID: 21107287; PMCID: PMC3075557.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    121. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010 Nov 01; 28(31):4747-54. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. PMID: 20921467; PMCID: PMC3020704.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    122. Short-term AMP-regulated protein kinase activation enhances insulin-sensitive fatty acid uptake and increases the effects of insulin on fatty acid oxidation in L6 muscle cells. Exp Biol Med (Maywood). 2010 Apr; 235(4):514-21. Kelly KR, Abbott MJ, Turcotte LP. PMID: 20407084.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    123. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg. 2010 Mar; 20(3):308-15. Navaneethan SD, Kelly KR, Sabbagh F, Schauer PR, Kirwan JP, Kashyap SR. PMID: 20217955; PMCID: PMC2891346.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    124. Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. J Thorac Oncol. 2009 Jul; 4(7):930-5. Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West HJ, Herbst R, Johnson D, Bunn P, Govindan R. PMID: 19550249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    125. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res (Phila). 2009 May; 2(5):440-9. Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE. PMID: 19401528; PMCID: PMC3103211.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    126. In Reply. Journal of Clinical Oncology. 2009 Jan 20; 27(3):465-467. Hirsch HF, Herbst HR, Olsen OC, Chansky CK, Crowley CJ, Kelly KK, Franklin FW, Bunn BP, Varella-Garcia VM, Gandara GD. .
      View in: Publisher Site   Mentions:
    127. In Reply. Journal of Clinical Oncology. 2009 Jan 1; 27(1):160-162. Simon SG, Verschragen VC, Janne JP, Langer LC, Dowlati DA, Gadgeel GS, Kelly KK, Kalemkerian KG, Traynor TA, Peng PG, Gill GJ, Obasaju OC, Kindler KH. .
      View in: Publisher Site   Mentions:
    128. In Reply. Journal of Clinical Oncology. 2008 Oct 10; 26(29):4850-4851. Kelly KK, Redman RM, Gandara GD. .
      View in: Publisher Site   Mentions:
    129. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008 Jul 20; 26(21):3567-72. Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. PMID: 18640937.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    130. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. PMID: 18612151; PMCID: PMC3368372.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCTClinical Trials
    131. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol. 2008 Jun; 3(6):664-73. Kelly K, Huang C. PMID: 18520811.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    132. Phosphatidylinositol 3-kinase-dependent insulin regulation of long-chain fatty acid (LCFA) metabolism in L6 muscle cells: involvement of atypical protein kinase C-zeta in LCFA uptake but not oxidation. J Endocrinol. 2008 Aug; 198(2):375-84. Kelly KR, Sung CK, Abbott MJ, Turcotte LP. PMID: 18480382.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    133. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20; 26(15):2450-6. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. PMID: 18378568.
      View in: PubMed   Mentions: 200     Fields:    Translation:HumansCTClinical Trials
    134. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jul; 61(1):82-90. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J. PMID: 18255187.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    135. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008 Jan 20; 26(3):463-7. Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR, Southwest Oncology Group. PMID: 18202421.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    136. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8. Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. PMID: 17909356.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    137. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol. 2007 Jun; 2 Suppl 2:S77-85. Rigas JR, Kelly K. PMID: 17589303.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    138. EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. Lancet Oncol. 2007 Jun; 8(6):559-60. Bemis LT, Robinson WA, McFarlane R, Buyers E, Kelly K, Varella-Garcia M, Mitchell JD, Franklin WA. PMID: 17540308.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    139. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718. J Thorac Oncol. 2007 May; 2(5):440-4. Hesketh PJ, Chansky K, Israel V, Grapski RT, Mekhail TM, Spiridonidis CH, Mills GM, Kelly K, Crowley JJ, Gandara DR. PMID: 17473660.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    140. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007 Mar; 18(3):453-60. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. PMID: 17322539.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    141. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2007 Mar; 8(5):335-8. Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA. PMID: 17562234.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    142. The promise of stereotactic body radiation therapy in a new era of oncology. Front Radiat Ther Oncol. 2007; 40:340-351. Kavanagh BD, Kelly K, Kane M. PMID: 17641518.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    143. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 01; 24(31):5025-33. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH. PMID: 17075122.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    144. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol. 2006 Nov; 1(9):991-5. Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR. PMID: 17409984.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    145. A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. International Journal of Radiation Oncology • Biology • Physics. 2006 Nov 1; 66(4):s120-s127. Schefter ST, Kavanagh KB, Raben RD, Kane KM, Chen CC, Stuhr SK, Kelly KK, Mitchell MJ, Bunn BP, Gaspar GL. .
      View in: Publisher Site   Mentions:
    146. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Sep 20; 24(27):4405-11. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA, Kelly K. PMID: 16983108.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    147. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer. 2006 Sep; 8(2):116-21. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara PN, Kelly K, Crowley J, Livingston R. PMID: 17026812.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    148. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2006 Aug 15; 107(4):781-92. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR. PMID: 16847887.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    149. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7. Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. PMID: 16797779.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    150. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res. 2006 Jun 15; 12(12):3652-6. Bunn PA, Dziadziuszko R, Varella-Garcia M, Franklin WA, Witta SE, Kelly K, Hirsch FR. PMID: 16778092.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    151. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs. 2006 May; 24(3):213-21. Sunpaweravong P, Magree L, Rabinovitch R, Bunn P, Kelly K. PMID: 16193241.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    152. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S93-7. Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. PMID: 16384543.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    153. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93. Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. PMID: 16246975.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    154. Management of a superior sulcus (pancoast) tumor. Oncology (Williston Park). 2005 Oct; 19(11):1515-20. Solomon B, Kelly KL. PMID: 16370449.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    155. The role of targeted agents in adjuvant therapy for non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5027s-5029s. Kelly K. PMID: 16000608.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    156. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s. Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C. PMID: 16000599.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    157. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005 Jun 01; 23(16):3752-9. Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR, Cancer and Leukemia Group. PMID: 15923572.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    158. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005 May 01; 23(13):3125-37. Gridelli C, Aapro M, Ardizzoni A, Balducci L, De Marinis F, Kelly K, Le Chevalier T, Manegold C, Perrone F, Rosell R, Shepherd F, De Petris L, Di Maio M, Langer C. PMID: 15860872.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    159. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005 May; 10(5):345-56. Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulières D, Saltz L, Leyden J. PMID: 15851793.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimals
    160. ACCO: ASCO core curriculum outline. J Clin Oncol. 2005 Mar 20; 23(9):2049-77. Muss HB, Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PW, Saltz L, Schapira L, Sparano J, American Society of Clinical Oncology. PMID: 15728218.
      View in: PubMed   Mentions: 14     Fields:    
    161. Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. Semin Oncol. 2004 Dec; 31(6 Suppl 11):3-7. Kelly K. PMID: 15599828.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    162. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2004 Nov 01; 10(21):7229-37. Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA, Chan DC, Pallansch P, Eckhardt SG. PMID: 15534096.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    163. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5439-46. Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn PA, Ettinger DS. PMID: 15328182.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    164. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res. 2004 Aug 01; 10(15):5022-6. Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR. PMID: 15297403.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    165. Treatment of thymoma: a comparative study between Thailand and the United States and a review of the literature. Am J Clin Oncol. 2004 Jun; 27(3):236-46. Sunpaweravong P, Kelly K. PMID: 15170141.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    166. Novel approaches for the treatment of small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):499-518. Wakelee H, Kelly K. PMID: 15094184.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    167. Gefitinib: phase II and III results in advanced non-small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):93-9. Kelly K, Averbuch S. PMID: 14981586.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    168. An elderly man with resectable lung cancer. Oncology (Williston Park). 2004 Feb; 18(2):234-40. Kelly K. PMID: 15008059.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    169. A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment. Depress Anxiety. 2004; 19(1):43-50. Mischoulon D, Opitz G, Kelly K, Fava M, Rosenbaum JF. PMID: 14978785.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    170. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003 Oct 22; 290(16):2149-58. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. PMID: 14570950.
      View in: PubMed   Mentions: 623     Fields:    Translation:HumansCTClinical Trials
    171. The benefits of achieving stable disease in advanced lung cancer. Oncology (Williston Park). 2003 Jul; 17(7):957-63; discussion 963, 968-70. Kelly K. PMID: 12886865.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    172. Treatment of non-small-cell lung cancer in older persons. Oncology (Williston Park). 2003 Jan; 17(1):31-9; discussion 43-4, 47-8. Basche M, Kelly K. PMID: 12599930.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    173. Randomized controlled trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary results. Radiology. 2002 Nov; 225(2):506-10. Garg K, Keith RL, Byers T, Kelly K, Kerzner AL, Lynch DA, Miller YE. PMID: 12409588.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    174. Current role of irinotecan in the treatment of non-small-cell lung cancer. Oncology (Williston Park). 2002 Sep; 16(9):1153-62, 1165; discussion 1165-6 passim. Kelly K. PMID: 12380945.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    175. Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res. 2002 Mar; 11(2):115-26. Moinpour CM, Lyons B, Grevstad PK, Lovato LC, Crowley J, Czaplicki K, Buckner ZM, Ganz PA, Kelly K, Gandara DR. PMID: 12018735.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    176. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst. 2002 Feb 20; 94(4):291-7. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, Gandara DR. PMID: 11854391.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    177. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):87-94. Bunn PA, Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, Piazza G, Whitehead CM, Pamukcu R, Thompson W, Alila H. PMID: 11894018.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    178. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Clin Cancer Res. 2001 Aug; 7(8):2325-9. Kelly K, Lovato L, Bunn PA, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley JJ, Gandara DR, Southwest Oncology Group. PMID: 11489808.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    179. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001 Jul 01; 19(13):3210-8. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. PMID: 11432888.
      View in: PubMed   Mentions: 237     Fields:    Translation:HumansCTClinical Trials
    180. Irinotecan in small-cell lung cancer: current data. Clin Lung Cancer. 2001 May; 2 Suppl 2:S4-8. Kelly K. PMID: 14725723.
      View in: PubMed   Mentions: 1     Fields:    
    181. Treatment of extensive stage small cell lung cancer. Cancer Treat Res. 2001; 105:253-76. Kelly K. PMID: 11224990.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    182. Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Clin Lung Cancer. 2000 Dec; 2 Suppl 1:S23-8. Bunn PA, Kelly K. PMID: 14725732.
      View in: PubMed   Mentions: 2     Fields:    
    183. The inherited nature of lung cancer: a pilot study. Lung Cancer. 2000 Nov; 30(2):135-44. Wood ME, Kelly K, Mullineaux LG, Bunn PA. PMID: 11086207.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    184. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2000 Sep; 6(9):3474-9. Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA. PMID: 10999731.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    185. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment? Chest. 2000 Apr; 117(4 Suppl 1):119S-122S. Bunn PA, Mault J, Kelly K. PMID: 10777465.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    186. New chemotherapy agents for small cell lung cancer. Chest. 2000 Apr; 117(4 Suppl 1):156S-162S. Kelly K. PMID: 10777472.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    187. New combinations in the treatment of lung cancer: a time for optimism. Chest. 2000 Apr; 117(4 Suppl 1):138S-143S. Bunn PA, Kelly K. PMID: 10777469.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    188. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3419-24. Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA. PMID: 10589753.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    189. Medical treatment of lung cancer. J Thorac Imaging. 1999 Oct; 14(4):257-65. Kelly K, Mikhaeel-Kamel N. PMID: 10524806.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    190. The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer. Ann Oncol. 1999; 10 Suppl 5:S53-6. Kelly K. PMID: 10582140.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    191. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998 Jul; 16(7):2459-65. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB. PMID: 9667264.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    192. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer. 1998 May; 20(2):85-91. Kelly K, Bunn PA. PMID: 9711526.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    193. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May; 4(5):1087-100. Bunn PA, Kelly K. PMID: 9607565.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    194. A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1998 Feb 01; 40(3):559-67. Kelly K, Hazuka M, Pan Z, Murphy J, Caskey J, Leonard C, Bunn PA. PMID: 9486605.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    195. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. Bunn PA, Kelly K. PMID: 9331140.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    196. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 1997 Jul; 3(7):1117-23. Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA. PMID: 9815791.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    197. Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer. Semin Oncol. 1997 Jun; 24(3 Suppl 8):S8-46-S8-52. Bunn PA, Kelly K. PMID: 9207318.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    198. Overview of the randomized phase III trials in non-small cell lung cancer in North America. Semin Oncol. 1997 Jun; 24(3 Suppl 8):S8-2-S8-5. Kelly K. PMID: 9207308.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    199. High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clin Cancer Res. 1997 Mar; 3(3):479-82. Scott FM, Modali R, Lehman TA, Seddon M, Kelly K, Dempsey EC, Wilson V, Tockman MS, Mulshine JL. PMID: 9815708.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    200. Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1996 Dec; 23(6 Suppl 16):11-5. Bunn PA, Kelly K. PMID: 9007114.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    201. Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction. Anal Biochem. 1996 Aug 01; 239(2):153-9. Lehman TA, Scott F, Seddon M, Kelly K, Dempsey EC, Wilson VL, Mulshine JL, Modali R. PMID: 8811898.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    202. Peptide amidating activity in human bronchoalveolar lavage fluid. Lung Cancer. 1996 Jun; 14(2-3):239-51. Scott FM, Treston AM, Shaw GL, Avis I, Sorenson J, Kelly K, Dempsey EC, Cantor AB, Tockman M, Mulshine JL. PMID: 8794407.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    203. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec; 13(12):2924-30. Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, et al. PMID: 8523056.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    204. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60. Bunn PA, Kelly KL. PMID: 7481862.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    205. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Aug; 22(4 Suppl 9):2-6. Bunn PA, Kelly K. PMID: 7644924.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    206. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995 Jul; 13(7):1632-41. Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR, et al. PMID: 7602352.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    207. New treatment agents for advanced small cell and non-small cell lung cancer. Semin Oncol. 1995 Jun; 22(3 Suppl 6):53-63. Bunn PA, Kelly K. PMID: 7597434.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    208. Re: Prophylactic cranial irradiation for patients with small-cell lung cancer. J Natl Cancer Inst. 1995 May 17; 87(10):766-7. Noell KT, Deland MM, Harwood AR. PMID: 7563157.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    209. Prophylactic cranial irradiation for patients with small-cell lung cancer. J Natl Cancer Inst. 1995 Feb 01; 87(3):161-2. Bunn PA, Kelly K. PMID: 7707398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    210. The role of routine chest radiotherapy in small-cell lung cancer. An issue of timing and stage. Chest. 1993 Sep; 104(3):661-2. Bunn PA, Kelly K. PMID: 8395999.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    211. Antigens in lung cancer: clinical radio-immunolocalization in lung cancer. Lung Cancer. 1993 Mar 1; 9(1-6):171-177. Bunn BP, Kelly KK. .
      View in: Publisher Site   Mentions:
    212. The role of GM-CSF in lung cancer: a review of the literature. Lung Cancer. 1993 Mar 1; 9(1-6):45-58. Paul PB, Karen KK. .
      View in: Publisher Site   Mentions:
    213. Prospective trial evaluating immunocytochemical-based sputum techniques for early lung cancer detection: assays for promotion factors in the bronchial lavage. J Cell Biochem Suppl. 1993; 17F:175-83. Scott F, Cuttitta F, Treston AM, Avis I, Gupta P, Ruckdeschel J, Kelly K, Piantadosi S, Tockman M, Mulshine J. PMID: 8412189.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    214. Growth factors in lung cancer: possible etiologic role and clinical target. Med Pediatr Oncol. 1991; 19(6):450-8. Kelly K, Kane MA, Bunn PA. PMID: 1660094.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells